European CHMP issues positive opinion for netarsudil (Rhokiinsa) for treatment of primary open-angle glaucoma or ocular hypertension

Source:
European Medicines Agency - EMA
Publisher:
European Medicines Agency
Publication date:
19 September 2019

Abstract

Netarsudil is a Rho kinase inhibitor that reduces intraocular pressure by increasing outflow of aqueous humor through the trabecular outflow pathway and reducing episcleral venous pressure. It will be available as a 200 microgram/ml eye drop solution.